{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-003023","form_type":"8-K","ticker":"NTRB","cik":"0001676047","company_name":"NutriBand Inc.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.074894+00:00","generated_at":"2026-06-07T00:35:05.763707+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch","bullets":["Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.","Agreement replaces prior feasibility deal; moves AVERSA Fentanyl toward NDA filing.","AVERSA Fentanyl estimated peak annual US sales $80M-$200M per Health Advances 2022 market analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-003023","json":"https://secwatch.observer/filing/0001213900-24-003023.json","markdown":"https://secwatch.observer/filing/0001213900-24-003023.md","text":"https://secwatch.observer/filing/0001213900-24-003023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676047/000121390024003023/0001213900-24-003023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676047/000121390024003023/ea191528-8k_nutriband.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:35:05.763707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}